Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic antifungal agents].

Carlos Lumbreras1, Manuel Lizasoain, José María Aguado

  • 1Unidad de Enfermedades Infecciosas. Hospital Universitario 12 de Octubre. Universidad Complutense de Madrid. España. clumbrerasb@medynet.com

Enfermedades Infecciosas Y Microbiologia Clinica
|October 4, 2003
PubMed
Summary

Antifungal medications have evolved significantly, with newer formulations and drug classes like triazoles and echinocandins offering improved safety and efficacy for invasive fungal infections compared to older treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same author

Evaluation of an Immune-guided Prevention Strategy Against CMV Among Intermediate-risk Kidney Transplant Recipients: A Quasi-experimental Study.

Transplantation·2026
Same author

Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of <i>clostridioides difficile</i> infection in patients receiving systemic antibiotic therapy (PREVAN trial).

JAC-antimicrobial resistance·2026
Same author

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.

Mycoses·2026
Same author

Appropriateness of malaria treatment according to World Health Organization criteria for severe malaria in a non-endemic country.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same author

How can we optimize the diagnostic and therapeutic approach of urinary tract infection? Expert opinion-based recommendations.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) are a major cause of mortality.
  • Amphotericin B was the sole antifungal treatment until the 1990s, despite significant toxicity.
  • Lipid formulations of amphotericin B have reduced associated side effects.

Purpose of the Study:

  • To review the advancements in antifungal therapies for invasive fungal infections.
  • To compare the efficacy and safety profiles of various antifungal agents.

Main Methods:

  • Literature review of antifungal drug development and clinical applications.
  • Comparative analysis of historical and contemporary antifungal treatments.

Main Results:

Related Experiment Videos

  • Lipid formulations of amphotericin B demonstrate reduced toxicity.
  • Triazoles (fluconazole, itraconazole, voriconazole) are safe and effective for various IFIs.
  • Voriconazole shows superior efficacy over amphotericin B for invasive aspergillosis.
  • Echinocandins (caspofungin) offer a new, safe class with activity against Candida and Aspergillus.

Conclusions:

  • Modern antifungal agents, including lipid-based amphotericin B, triazoles, and echinocandins, have significantly improved the management of invasive fungal infections.
  • These newer agents offer better safety profiles and targeted efficacy against specific fungal pathogens.